Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mersana Therapeutics Inc MRSN

Healthcare Biotechnology
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed... see more

Recent & Breaking News (NDAQ:MRSN)

Mersana Therapeutics Announces Third Quarter 2018 Financial Results and Provides Business Updates

GlobeNewswire November 13, 2018

Mersana Therapeutics Presents Pre-clinical Data at AACR-NCI-EORTC on Two Additional, Proprietary Antibody Drug Conjugate Platforms and a Pre-clinical Update for XMT-1522 in Non-small Cell Lung Cancer

GlobeNewswire November 12, 2018

Mersana Scientists Present Updates on XMT-1522, XMT-1536 and the Dolaflexin Platform at World ADC 2018

GlobeNewswire November 12, 2018

Mersana Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference

GlobeNewswire November 8, 2018

Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2018 Financial Results and Business Updates

GlobeNewswire November 6, 2018

Mersana Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire September 26, 2018

Mersana Therapeutics Presents New Preclinical Data on XMT-1536 at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer

GlobeNewswire September 25, 2018

Mersana Announces FDA Lifts Partial Clinical Hold for XMT-1522

GlobeNewswire September 17, 2018

Mersana Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire August 30, 2018

Mersana Therapeutics Announces Second Quarter 2018 Financial Results and Provides Business Updates

GlobeNewswire August 14, 2018

Mersana Therapeutics to Present at the Wedbush PacGrow Healthcare Conference

GlobeNewswire August 8, 2018

Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2018 Financial Results and Business Updates

GlobeNewswire August 8, 2018

Mersana Presents Interim Dose-Escalation Data on XMT-1522 in Select Cancers at ASCO 2018

GlobeNewswire June 4, 2018

Mersana Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire May 31, 2018

Mersana Therapeutics Announces First Quarter 2018 Financial Results and Provides Business Updates

GlobeNewswire May 14, 2018

Mersana Therapeutics to Host Conference Call Announcing First Quarter 2018 Financial Results and Business Updates

GlobeNewswire May 7, 2018

Mersana Therapeutics to Present at the Deutsche Bank 43rd Annual Health Care Conference

GlobeNewswire May 1, 2018

Mersana Therapeutics Presents Preclinical Data Further Demonstrating Differentiating Aspects of Its ADC Platform Technology at AACR 2018

GlobeNewswire April 17, 2018

Mersana Therapeutics Announces Poster Presentations Demonstrating Differentiating Aspects of ADC Platform Technology at the American Association for Cancer Research Annual Meeting 2018

GlobeNewswire April 9, 2018

Mersana Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates

GlobeNewswire March 28, 2018